ARS Pharmaceuticals, Inc. financial data

Symbol
SPRY on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 09 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 741% % -62%
Quick Ratio 50% %
Debt-to-equity 96% % 611%
Return On Equity -100% % -2912%
Return On Assets -51% % -1726%
Operating Margin -213% % -6057%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 99,297,307 shares 1.2%
Common Stock, Shares, Outstanding 99,290,926 shares 1.4%
Entity Public Float $1,094,900,000 USD 135%
Common Stock, Value, Issued $10,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 98,566,481 shares 1.7%
Weighted Average Number of Shares Outstanding, Diluted 98,566,481 shares -3.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $84,278,000 USD -5.5%
Research and Development Expense $13,181,000 USD -33%
General and Administrative Expense $38,700,000 USD -1.1%
Operating Income (Loss) $179,448,000 USD -5721%
Net Income (Loss) Attributable to Parent $171,298,000 USD -2242%
Earnings Per Share, Basic -1.74 USD/shares -2275%
Earnings Per Share, Diluted -1.74 USD/shares -2275%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $41,317,000 USD -19%
Accounts Receivable, after Allowance for Credit Loss, Current $25,347,000 USD 210%
Inventory, Net $31,422,000 USD 199%
Assets, Current $284,896,000 USD -15%
Property, Plant and Equipment, Net $2,465,000 USD 131%
Operating Lease, Right-of-Use Asset $1,439,000 USD 1464%
Intangible Assets, Net (Excluding Goodwill) $14,452,000 USD 96%
Assets $327,652,000 USD -6.7%
Accounts Payable, Current $5,725,000 USD -42%
Employee-related Liabilities, Current $5,448,000 USD
Contract with Customer, Liability, Current $609,000 USD 9.3%
Liabilities, Current $39,145,000 USD 67%
Contract with Customer, Liability, Noncurrent $1,130,000 USD -26%
Operating Lease, Liability, Noncurrent $949,000 USD
Liabilities $213,394,000 USD 126%
Accumulated Other Comprehensive Income (Loss), Net of Tax $125,000 USD -43%
Retained Earnings (Accumulated Deficit) $294,603,000 USD -139%
Stockholders' Equity Attributable to Parent $114,258,000 USD -56%
Liabilities and Equity $327,652,000 USD -6.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $40,742,000 USD -507%
Net Cash Provided by (Used in) Financing Activities $725,000 USD 181%
Net Cash Provided by (Used in) Investing Activities $29,064,000 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 99,290,926 shares 1.4%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $10,953,000 USD 27%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41,317,000 USD -19%
Deferred Tax Assets, Valuation Allowance $73,406,000 USD 99%
Deferred Tax Assets, Gross $73,406,000 USD 99%
Operating Lease, Liability $1,532,000 USD 1402%
Depreciation $11,000 USD -45%
Payments to Acquire Property, Plant, and Equipment $91,000 USD 9.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $171,393,000 USD -2198%
Lessee, Operating Lease, Liability, to be Paid $1,854,000 USD 1683%
Property, Plant and Equipment, Gross $748,000 USD 15%
Operating Lease, Liability, Current $583,000 USD 472%
Lessee, Operating Lease, Liability, to be Paid, Year Two $627,000 USD 1393%
Lessee, Operating Lease, Liability, to be Paid, Year One $609,000 USD 882%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $322,000 USD 16000%
Lessee, Operating Lease, Liability, to be Paid, Year Three $318,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $32,250,000 USD 151%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $7,334,000 USD 4.4%
Operating Lease, Payments $141,000 USD 127%
Additional Paid in Capital $408,726,000 USD 7.6%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets $800,000 USD 700%
Deferred Tax Assets, Net of Valuation Allowance $73,800,000 USD 99%
Share-based Payment Arrangement, Expense $14,534,000 USD 57%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%